Inclusion Criteria:

• Minimal eligibility: See the following (2 to 3).
• KIR typing will be undertaken after informed consent is signed.
• HLA typing will be undertaken independent of consent.
• Inclusion criteria for recipient (within 4 weeks prior to lymphodepleting conditioning regimen and after consent-signing). As following (5 to 18).
• HLA-haploidentical relative is predicted to be alloreactive based upon the presence of the relevant KIR genes and incompatibility with the recipient. Three conditions must be met simultaneously: a) The KIR-ligand (HLA molecule) for the KIR-receptor gene in question must be ABSENT in the recipient. b) The KIR-receptor gene in question must be PRESENT,that is, not deleted in the DONOR. c) The KIR-ligand (HLA molecule) for the KIR-receptor gene in question must be PRESENT in the donor.
• Progression of neuroblastoma after autologous peripheral blood stem-cell transplantation
• Measurable neuroblastoma disease as defined by at least one radiographic (using any/all of the following modalities CT, MRI, PET, MIBG, Bone scan), abnormality attributed to malignancy
• Platelets >/= 50,000 x 10^ 9/L and hemoglobin (Hgb) >/= 9 g/dL, unsupported by transfusions in last seven days.
• ANC >/= 1,000 x 10^ 9/L, unsupported by cytokines in last seven days.
• Off prednisone or other immunosuppressive medications for at least 3 days
• Zubrod performance scale </= 2 or Lansky >/= 60.
• Adequate renal function defined as: Serum creatinine (Cr), for adults </=2 mg/dL, for children </=2 mg/dL or </=2 times upper limit of normal (ULN) for age (whichever is less). If abnormal renal function then Cr clearance >60 mL/min/1.73m^2.
• Adequate liver function defined as: Total bilirubin </=2 mg/dL and SGPT (ALT) </= 2.5 x ULN for age (unless Gilbert's disease or abnormal liver function due to primary disease).
• Pulmonary symptoms controlled by medication and pulse oximetry >/= 92% room air.
• Negative serum test to rule out pregnancy within 2 weeks prior to registration in females post menarche of childbearing potential (non childbearing is defined as greater than one year post-menopausal or surgically sterilized).
• Requirement of males and females of childbearing potential to use any form of contraception considered effective and medically acceptable by the Investigator.
• Negative serology for (HIV)human immunodeficiency virus.
• Not a breast-feeding female.
• Inclusion criteria for recipient to receive NK infusion(s) as assessed on Day 0. As following (20 to 29).
• Not currently using a ventilator.
• Not currently undergoing dialysis.
• Not currently using a Phase I, II, or III investigational agent. These agents should be stopped within 21 days of NK infusion.
• No requirement for supplemental oxygen.
• No new detected cardiac arrhythmia not controlled with medical management within prior 72 hour period.
• No hypotension requiring pressor support within prior 72 hour period.
• No uncontrolled infection defined as daily fever >/= 38.2 degrees Celsius and no new positive culture for bacteria, fungus, or virus within 72 hours prior to NK-cell infusion, if clinically indicated.
• No ascites requiring paracentesis within prior 72 hour period.
• No seizure activity or clinically detectable encephalopathy or new focal neurologic deficits within prior 72 hour period.
• Not taking corticosteroids by mouth or intravenously within prior 72 hour period.
• Inclusion criteria for donor (within 7 days of apheresis). See following (31 to 40).
• Related to recipient.
• Able and willing to undergo apheresis.
• Willing (but not required) to donate blood for NK cell studies.
• Willing to donate blood for baseline chimerism studies.
• Willing to donate blood for baseline fluorescence in situ hybridization studies.
• Screening infectious disease panel that meets standard medical eligibility criteria for allogeneic blood stem cell donation.
• CBC, differential and platelet studies that meet standard medical eligibility criteria for allogeneic blood stem cell donation.
• Negative serum test to rule out pregnancy within two weeks prior to registration in females of childbearing potential (non-childbearing is defined as greater than one year post-menopause or surgically sterilized).
• Meet standard medical eligibility criteria for allogeneic blood stem cell donation.
• The first two patients enrolled in this protocol will need to have prior cryopreserved autologous peripheral blood stem cells collected within 6 months and/or they are at least 6 months after autologous peripheral blood stem cell rescue. This criterion safeguards against the possibility that the lymphodepletion regimen may lead to prolonged myelosuppression.

Exclusion Criteria:

• Exclusion criteria for donor:(within 7 days of apheresis). As following 2) to 3)

• Active infection.

  1. Febrile
  2. on antibiotics.
• Breast-feeding female.